B cells as therapeutic targets for rheumatic diseases

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 180-185

  Looney, R John ^a,b   Anolik, Jennifer ^a   Sanz, Inãki ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Anti BlyS; Anti CD154; Anti CD20; Anti neutrophil cytoplasmic antibodies + vasculitis; B cells; Cryoglobulinemia; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; ALPHA INTERFERON; B LYMPHOCYTE ANTIGEN; BLYS MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LJP 1082; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALF LIFE TIME; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CD40 LIGAND; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGANIC CHEMICALS; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES;

EID: 1942531960     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00003     Document Type: Review

References (53)

1. Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. Demonstrates the natural history of humoral autoimmunity before the onset of clinical disease.
2. Shlomchik MJ, Madaio MP, Ni D, et al.: The role of B cells in Ipr/Ipr-induced autoimmunity. J Exp Med 1994, 180:1295-1306.
3. Chan OT, Hannum LG, Haberman AM, et al.: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1648.
4. Golay JT, Clark EA, Beverly PCL: The CD20 (Bp35) antigen is involved in activation of B cells from G0 to the G1 phase of the cell cycle. J Immunol 1985, 135:3795-3801.
5. Tedder TF, Boyd AW, Freedman AS, et al.: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985, 135:973-979.
6. Tedder TF, Engel P: CD20: a regulator of cell-cycle progression of B-lymphocytes. Immunol Today 1994, 15:450-454.
7. Press OW, Howell-Clark J, Anderson S, et al.: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994, 83:1390-1397.
8. Pascual V, Liu YJ, Capra D: Normal human B cell sub-populations and their malignant counterparts. Baillieres Clin Haematol 1997, 10:525-538.
9. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
10. Leonard JP, Coleman M, Ketas JC, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3051-3059.
11. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001, 40:205-211.
12. Stahl HD, Szczepanski L, Szechinski J, et al: Rituximab in RA: efficacy and safety from a randomized controlled trial. Ann Rheum Dis 2003, 62:S65. Presents the 6-months efficacy data for the first randomized, double-blind, placebo-controlled trial of B cell depletion in an autoimmune disease.
13. Emery P, Szczepanski L, Szechinski J, et al.: Sustained efficacy at 48 weeks after a single treatment course of rituximab in patients with RA. Arthritis Rheum 2003, 48:S439. Presents the 1-year follow-up efficacy data for the trial in [12].
14. Csuka M, Carrera GF, McCarty DJ: Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a follow-up study. JAMA 1986, 255:2315-2319.
15. Anolik JH, Campbell D, Felgar RE, et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48:455-459. Investigates the effects of genetic variation on the effectiveness of B cell depletion by anti-CD20 monoclonal antibody.
16. Anolik JH, Campbell D, Felgar R, et al.: B lymphocyte depletion in the treatment of systemic lupus: phase I/II trial of rituximab in SLE. Arthritis Rheum 2002, 47:S289. A dose-escalation study of rituximab in SLE, demonstrating variability in the effectiveness of B cell depletion. Patients in whom B cells depleted well improved clinically.
17. Bhat NM, Lee LM, van Vollenhoven RF, et al.: VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype. J Rheumatol 2002, 29:2114-2121. Establishes serum levels of IgG VH4-34 as a marker for SLE.
18. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al.: Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001, 108:1061-1070.
19. Albert DA, Khan SR, Stansberry J, et al.: A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus. American College of Rheumatology Annual Meeting October 2003; Orlando, Florida. Demonstrates good B cell depletion in most SLE patients with full-dose rituximab as monotherapy.
20. Leandro MJ, Edwards JC, Cambridge G, et al.: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677. An open study of rituximab in combination with glucocorticoids and cyclophosphamide. Combination therapy consistently depleted B cells well and was associated with a marked improvement in global lupus activity.
21. Leandro MJ, Ehrenstein MR, Edwards JC, et al.: Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 2003, 48:S378. An open study of rituximab, cyclophosphamide, and steroids in patients with nephritis not responding to conventional therapy. Global lupus activity, serology, and renal parameters all appeared to improve.
22. Boletis JN, Sfikakis PP, Lionaki SJ, et al.: An open study of B cell depletion in patients with proliferative lupus nephritis: preliminary results. J Am Soc Nephrol 2003, 14:379A. An open study of rituximab in combination with moderate-dose steroids in the treatment of class III and IV lupus nephritis. Both serology and renal parameters improved without the need for cyclophosphamide or other immunosuppressive agents.
23. Bussel JB: Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol 2000, 27(Suppl 12):91-98.
24. Patel K, Berman J, Ferber A, et al.: Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001, 67:59-60.
25. Stasi R, Pagano A, Stipa E, et al.: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
26. Berentsen S, Tjonnfjord GE, Brudevold R, et al.: Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001, 115:79-83.
27. Quartier P, Brethon B, Philippet P, et al.: Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001, 358:1511-1513.
28. Zecca M, Nobili B, Ramenghi U, et al.: Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003, 101:3857-3861. Rituximab was used in infants and very young children. Replacement IVIG was given for 6 months. Treatment appeared to be effective and safe.
29. Ruggenenti P, Chiurchiu C, Brusegan V, et al.: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003, 14:1851-1857. An open trial in eight patients with resistant membranous nephritis. Proteinuria in most patients improved; nearly complete resolution was seen in two patients.
30. Levine TD: A pilot study of rituximab therapy for dermatomyositis. Arthritis Rheum 2002; 46. An open study treating five dermatomyositis patients with rituximab.
31. Zaja F, De Vita S, Mazzaro C, et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834. A report of dramatic response of skin and musculoskeletal manifestations in mixed cryoglobulinemia. Most of the patients were infected with hepatitis C. There was an increase in viral titers but no deterioration in liver function.
32. Sansonno D, De Re V, Lauletta G, et al.: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101:3818-3826. See [31••].
33. Xiao X, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963. Demonstration that ANCAs are pathogenic using passive transfer of anti-myeloperoxidase antibodies to RAG KO mice.
34. Specks U, Ferenza FC, McDonald TJ, et al.: Response of Wegener's granulomatosis to rituximab therapy. Arthritis Rheum 2001, 44:2836-2840. The results of using rituximab in ANCA-associated vasculitis were surprisingly positive.
35. Eriksson P: Short term outcome and safety in 5 patients with ANCA-positive vasculitis treated with rituximab: 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res 2003, 26:294. See [34•].
36. Jayne D, Burns S, Smith K: A prospective, open label trial of B-cell depletion with rituximab in refractory systemic vasculitis. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res 2003, 26:294. See [34•].
37. Bader-Meunier B, Gabolde M, Casadevall N, et al.: Life threatening complication of rituximab in a child. Haematologica 2002, 87:ECR45.
38. Szechinski J, Szczepanski L, Fillopowicz-Sosnowska A, et al.: safety data from 48 weeks follow-up of a randomized controlled trial of rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:S121. A presentation of safety data for the trial described in [12] and [13].
39. Binstadt BA, Caldas AC, Turvery SE, et al.: Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003, 143:598-604. Rituximab was used in four pediatric patients with systemic autoimmunity. Decreased IgG levels were seen and treated with IVIG.
40. Van der Kolk LE, Baars JW, Prins MH, et al.: Rituximab treatment results in impaired secondary humoral responses. Blood 2002, 100:2257-2259. The use of rituximab in lymphoma patients was associated with loss of secondary immune responses.
41. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1417-1429. An excellent review of CD154-CD40 in B cell biology.
42. Boumpas DT, Furie R, Manzi S, et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727. Well-designed clinical trials used anti-CD154 in SLE. Unfortunately, the first trial was halted because of toxicity, and the second trial did not find demonstrate a beneficial effect.
43. Kalunian KC, Davis JC Jr, Merrill JT, et al.: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258. See [42•].
44. Huang W, Sinha J, Newman J, et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002, 46:1554-1562. B cell biology was investigated in small numbers of patients who completed the trial described in [42]. Dramatic effects of B cells were seen, suggesting that anti-CD154 therapy should be effective if its toxicity can be understood and circumvented.
45. Grammer AC, Slota R, Fischer R, et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520. See [44••].
46. Kelsoe G: Therapeutic CD154 antibody for lupus: promise for the future? J Clin Invest 2003, 112:1480-1482. A beautiful review of germinal center biology and the effects of anti-CD154 in SLE.
47. Stohl W: Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002, 14:522-528. An excellent review of BlyS in SLE.
48. Avery DT, Kalled SL, Ellyard JI, et al.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297. Demonstration that BAFF is important in plasmablast survival, suggesting that the increased levels of BAFF seen in patients with active SLE may be linked to the increase in circulating plasmablasts that has also been seen in these patients.
49. Halpern WBG, Lappin P, Zanardi T, et al.: Effects of lymphostat-B, a BlyS antagonist, when administered intravenously to cynomologus Monkeys. Arthritis Rheum 2003, 48:S594. An evaluation of the pharmacology and effect on B cells of a monoclonal antibody that neutralized BLyS in primates.
50. Safety: Pharmacokinetics and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BlyS) in SLE patients. Arthritis Rheum 2003, 48:3377. See [49••].
51. Alacron-Segovia D, Tumlin JA, Furie RA, et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:442-454. B cell tolerogens were demonstrated to be safe and able to lower autoantibody titers. However, clinical benefits have been difficult to document.
52. Cardiel MH, Tumlin JA, Furie RA, et al.: Clinical efficacy results from a RCT of LJP 394 in SLE patients with a history of renal disease. Arthritis Rheum 2003, 48:S582. See [51•].
53. Hirizon A, Weisman MH, Wallace DJ, et al.: Results of a randomized, placebo controlled, double blind phase 1/2 clinical trial (RCT) to assess the safety and tolerability of LJP 1082 in patients with antiphospholipid syndrome. Arthritis Rheum 2003, 48:S364. See [51•].